Document Detail

Tofacitinib in active ulcerative colitis.
MedLine Citation:
PMID:  23150970     Owner:  NLM     Status:  In-Data-Review    
To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are surprisingly ineffective in the treatment of Crohn's disease.(2) In Crohn's disease, the major cytokines arise from the differentiation of two subtypes of CD4+ T cells - Th1 and Th17 - whereas in ulcerative colitis a Th2-like differentiation process seems to be involved. Several recent reports on different experimental models seem to indicate that JAK inhibitors such as tofacitinib suppress Th2 but potentiate Th1 and Th17 responses. For example, . . .
Stéphane Paul; Xavier Roblin
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  367     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1959-61     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Thyroid nodules with indeterminate cytology.
Next Document:  Tofacitinib in active ulcerative colitis.